People usually find DCA the same way. Not through a big ad campaign. Not because it is trendy. They find it when they are stuck.
Sometimes it is cancer, and standard options are no longer working, or the side effects have become too much. Sometimes it is endometriosis, and the familiar cycle of hormones, surgery, and pain management stops feeling like a real plan.
This page is not meant to be the full story. It is a starting point.
Below you will find two paths: DCA for cancer and DCA for endometriosis. Each path links to a larger collection of documented cases, references, and practical “what happened next” write-ups.
If you are looking for quick clarity, start here, then follow the article that matches your situation.
DCA and Cancer: Case Reports
Cancer care is often presented as a fixed path: follow the protocol and accept what comes. Yet in real life, patients and families keep asking questions, especially when standard options have been exhausted. They look for approaches that combine biological rationale, documented outcomes, and hope that is grounded in reason.
Sodium dichloroacetate (DCA) sits in that space between formal research and lived experience. Over the past two decades it has developed a strong scientific rationale as a metabolic therapy, along with an expanding set of human case reports that track symptoms, tumor markers, and imaging over time. These are not vague stories; they include measurable changes that can be examined and questioned.
The cases presented here, both monotherapy and combination approaches, document what happens when DCA is used deliberately, thoughtfully, and often after conventional treatment had failed.
What follows are documented clinical outcomes of DCA used alone or in combination, with observable changes in symptoms, tumor markers, and imaging findings that challenge the idea that nothing more can be done.
Metastatic melanoma
Reduced Tumor Size, Stable Disease Over Time
This case involves a 32-year-old man diagnosed with stage III BRAF-positive melanoma – an aggressive skin cancer that repeatedly returned despite multiple standard treatments. Over six years, he underwent at least five surgeries, a course of interferon-alpha (which he stopped due to severe side effects), and later, a naturopathic regimen. Unfortunately, none provided lasting relief. The cancer kept coming back, spreading to his lymph nodes and causing pain.
Facing limited options and worsening disease, the patient began oral Sodium dichloroacetate (DCA) therapy. His daily protocol included DCA (1500 mg daily), along with supplements like benfotiamine, alpha-lipoic acid, and acetyl-L-carnitine. He followed a structured cycle: two weeks on, one week off.
The goal wasn’t dramatic tumor shrinkage but to slow the cancer’s pace. Surprisingly, that’s exactly what happened – and more. Scans showed marked tumor reduction, followed by long-term stability. Over four years, the disease stopped progressing. Pain eased, appetite returned, energy improved, and he resumed normal life with only mild, reversible side effects.
This quiet plateau – in a cancer known for relentless progression and frequent relapse – is remarkable. Imaging confirmed no new spread. The cancer appeared to pause rather than push forward. No further conventional treatment was needed during this period, and quality of life remained consistently high.
This case doesn’t claim a cure. But it adds to the growing body of real-world evidence that DCA may help shrink and stabilize difficult cancers, especially when other treatments fail. It highlights a possibility that deserves closer attention: that some low-toxicity metabolic therapies may offer durable control where few options remain.
Read the full case.
Medullary Thyroid Carcinoma (Metastatic, Relapsed)
Marked Tumor Marker Drop and Widespread Disease Control with DCA
This case follows a 51-year-old man diagnosed with medullary thyroid carcinoma (MTC), a rare and difficult-to-treat cancer. Despite multiple surgeries and rounds of chemotherapy (including regimens with DTIC, 5-fluorouracil, carboplatin, etoposide, and mitomycin C) the disease returned again and again, eventually spreading to the lymph nodes, bones, and mediastinum.
After several years his blood calcitonin (a blood marker that closely tracks disease activity in MTC) had soared to over 38,000 pg/ml (normal <20), and imaging showed widespread metastases. Several attempts with targeted agents and palliative therapies like Sandostatin and Samarium-153 brought no durable relief. At this point, he was ineligible for further clinical trials and faced a poor prognosis.
Out of conventional options, he began oral DCA at 10 mg/kg along with 750 mg of thiamine daily to prevent nerve-related side effects. Within weeks, his tumor markers began to fall. In just a few months, they dropped by more than fourfold, showing a steep and steady decline. What had once been climbing relentlessly was now falling rapidly – a strong early sign that the cancer was finally losing ground.
PET scans confirmed what blood tests suggested: a significant reduction in both the size and number of metastatic lesions, particularly in the lumbar spine, pelvis, and thoracic region. Central necrosis within mediastinal tumors increased, suggesting tumor breakdown.
DCA was well tolerated. Apart from routine monitoring, no additional treatment was required. The man continued the protocol without experiencing significant side effects.
This case illustrates a notable response to DCA in a person with terminal, treatment resistant MTC. In a cancer known for stubborn relapse and few lasting treatment options, the outcome offers a well-documented example of reduced tumor activity and prolonged disease control – achieved with Sodium dichloroacetate alone. It adds meaningful weight to the growing interest in DCA for aggressive endocrine cancers like MTC.
Read the full case.
Colorectal Cancer (Stage IV)
Long-term Disease Stabilization
This case follows a 57-year-old woman living with stage IV colorectal cancer involving an annular rectal tumor, multiple liver metastases, and microscopic pulmonary spread. Following surgery to relieve obstruction, she received chemotherapy with FOLFIRI and bevacizumab. The initial response was strong: liver lesions and the primary tumor regressed, and carcinoembryonic antigen (CEA) decreased from 260.9 ng/mL to 3.5 ng/mL. Over time, however, the response plateaued, and treatment shifted from tumor reduction to maintaining stability.
An integrative metabolic approach was introduced, centred on Sodium dichloroacetate (DCA) alongside nutraceutical support intended to minimize adverse reactions, including benfotiamine and alpha-lipoic acid. DCA was administered first intravenously and later orally on a cyclical schedule, coordinated with chemotherapy timing. Apart from mild transient sedation and reversible neuropathy at higher doses, treatment was well tolerated.
Imaging after four months showed stable disease, and subsequent scans demonstrated reduction or disappearance of liver lesions without new metastases. Chemotherapy was eventually discontinued due to side effects, while DCA therapy continued alone. Over nearly four years of follow-up, serial CT scans revealed no meaningful progression and CEA remained essentially unchanged (3.5 to 3.7 ng/mL).
Clinically, the patient remained functional, required less analgesia, and continued normal daily activities, including running her business. Total survival reached six years from diagnosis, with approximately 46 months of stability during DCA therapy without active chemotherapy – substantially longer than the typical 9–12 month expectation for advanced disease.
In metastatic colorectal cancer, where time is often measured in narrowing windows, this period of sustained stability stands as a carefully documented account of what was possible for one individual.
Read the full case story.
Non-Hodgkin’s lymphoma (Follicular B-cell)
Complete Remission After Relapse
A 48-year-old man with stage IV follicular B-cell non-Hodgkin lymphoma first presented with five months of progressive symptoms including a 50-pound weight loss, persistent fever, drenching night sweats, and extensive cervical lymphadenopathy extending from the upper neck to the clavicle. Imaging revealed pathological lymph nodes in the head, neck, chest, abdomen, and pelvis, and biopsy of lymph node and bone marrow confirmed advanced disease.
He underwent six cycles of R-CHOP chemotherapy and achieved complete remission, returning to normal daily activities for approximately one year. The disease then relapsed, marked by renewed fevers, night sweats, fatigue, weight loss, and enlarged lymph nodes in the neck and nasopharyngeal region. Further chemotherapy was recommended, but the man declined due to prior treatment intolerance.
He instead began oral sodium dichloroacetate (DCA) therapy at 1000 mg daily, accompanied by thiamine and alpha-lipoic acid to reduce the risk of neuropathy. Within two weeks systemic symptoms began improving, and lymph node enlargement progressively regressed. By approximately ten weeks symptoms had resolved completely.
A PET scan performed four months after initiating DCA demonstrated complete metabolic remission, with disappearance of previously active lymphoma sites. He continued maintenance DCA intermittently several times per week, and serial imaging over the following years showed no recurrence. Laboratory studies remained stable and no significant adverse effects were reported.
At last follow-up more than four years after relapse, he remained in full remission, working full-time and functioning normally. In a lymphoma subtype characterized by repeated cycles of remission and recurrence, this case documents sustained remission following relapse during continued DCA therapy.
Read the full case.
Recurrent Glioblastoma Multiforme
Prolonged Disease Control Observed with Sodium Dichloroacetate Therapy
This case follows a patient with recurrent glioblastoma multiforme, a diagnosis where the return of disease often signals rapid progression despite treatment. After surgery, radiation, and chemotherapy, the tumor came back. At that point, options were limited and the outlook was largely palliative. It was in this setting that oral DCA was introduced as a single metabolic therapy.
DCA was taken continuously over many months, with the dose adjusted along the way to limit side effects. The treatment was generally well tolerated. Some reversible peripheral neuropathy developed, but this improved with dose reduction and did not require stopping therapy. Gradually, imaging began to tell a different story. Serial MRI and PET scans showed a steady decline in tumor activity, eventually leading to an apparent radiologic resolution after around 15 months of DCA alone.
What adds weight to this case is what was seen beyond the scans. Tumor tissue examined after treatment showed fewer dividing cells and more signs of programmed cell death, including in tumor stem-like cells that are often linked to recurrence. Clinically, the patient remained stable throughout this period.
In a disease where recurrence usually marks the start of a rapid downhill course, this case stands out for both the depth and durability of response. It reflects the experience of one individual, but it offers a carefully observed account of prolonged disease control in recurrent glioblastoma during treatment with oral sodium dichloroacetate.
Read the full case.
Metastatic Cancer of Unknown Origin
Significant Pain Relief and Local Tumor Stabilization
This case follows a 71-year-old man living with a poorly differentiated carcinoma of unknown origin, with metastases affecting his right leg and liver. By the time sodium dichloroacetate (DCA) was considered, the illness had already taken a heavy toll. The most pressing problem was pain – deep, persistent pain in his right calf that shaped his days and limited his movement.
Standard approaches had been tried. He underwent radiotherapy and relied on escalating doses of pain medication, including opioids, yet the relief was incomplete and fragile. Chemotherapy was discussed, but in a palliative setting, its uncertain benefit and potential side effects weighed heavily.
In that context, oral DCA was introduced as an off-label option, not with the aim of shrinking tumors, but to see whether his symptoms could be better controlled. It was taken on a cyclical schedule, alongside supportive supplements intended to keep it safe.
What followed was a meaningful shift in his daily experience. Within weeks, his leg pain eased noticeably. The swelling in his calf reduced, and imaging showed that the local tumor burden had stabilised. Just as importantly, he needed fewer doses of breakthrough pain medication, allowing him greater comfort and mobility.
The treatment was well tolerated, with no serious side effects reported. While the cancer itself remained advanced, the improvement in quality of life was clear – something that had proven difficult to achieve with earlier interventions.
At follow-up, the benefit had held. In palliative care, where gains are often small and hard-won, this case offers a carefully observed account of sustained pain relief and local disease stability during treatment with oral sodium dichloroacetate alone.
Read the full case.
Metastatic Colorectal Cancer
Significant Pain Relief and Local Tumor Stabilization
This case follows a 71-year-old man living with a poorly differentiated carcinoma of unknown origin, with metastases affecting his right leg and liver. By the time sodium dichloroacetate (DCA) was considered, the illness had already taken a heavy toll. The most pressing problem was pain – deep, persistent pain in his right calf that shaped his days and limited his movement.
Standard approaches had been tried. He underwent radiotherapy and relied on escalating doses of pain medication, including opioids, yet the relief was incomplete and fragile. Chemotherapy was discussed, but in a palliative setting, its uncertain benefit and potential side effects weighed heavily.
In that context, oral DCA was introduced as an off-label option, not with the aim of shrinking tumors, but to see whether his symptoms could be better controlled. It was taken on a cyclical schedule, alongside supportive supplements intended to keep it safe.
What followed was a meaningful shift in his daily experience. Within weeks, his leg pain eased noticeably. The swelling in his calf reduced, and imaging showed that the local tumor burden had stabilised. Just as importantly, he needed fewer doses of breakthrough pain medication, allowing him greater comfort and mobility.
The treatment was well tolerated, with no serious side effects reported. While the cancer itself remained advanced, the improvement in quality of life was clear – something that had proven difficult to achieve with earlier interventions.
At follow-up, the benefit had held. In palliative care, where gains are often small and hard-won, this case offers a carefully observed account of sustained pain relief and local disease stability during treatment with oral sodium dichloroacetate alone.
Read the full case.
Metastatic Pancreatic Neuroendocrine Cancer
Liver Metastases Shrink After Dichloroacetate Therapy When Chemotherapy Failed
This case follows a 10-year-old boy diagnosed with metastatic neuroendocrine pancreatic carcinoma, a rare and aggressive cancer in childhood. At diagnosis, scans showed a tumor in the pancreas with extensive spread to the liver. He was treated initially with standard chemotherapy using cisplatin and etoposide, which led to an early reduction in tumor burden. That response, however, did not last. Over time, the disease progressed, and his condition worsened, marked by increasing fatigue, weight loss, nausea, and vomiting.
As treatment options narrowed, more intensive approaches (including high-dose chemotherapy and liver transplantation) were discussed but ultimately ruled out. With conventional therapy exhausted, an integrative approach was explored. In this setting, DCA was introduced, not as a stand-alone treatment, but alongside supportive metabolic therapies such as intravenous vitamin C, alpha-lipoic acid, amino acids, and minerals. Octreotide was also used initially.
Treatment began soon after the most recent imaging. Over the following weeks, repeat scans showed a measurable reduction in several liver metastases, with some lesions shrinking by around two centimetres. No new metastatic disease was identified during this period.
The treatment was generally well tolerated. Although there were brief increases in pain following infusions, these were managed with supportive care. Importantly, the child’s overall clinical stability improved, allowing treatment to continue for several months.
At follow-up, the case stood out for its reduction in liver tumor burden and short-term disease stabilisation after chemotherapy failure. While the combined nature of the treatment means the effects cannot be attributed to DCA alone, this report offers a carefully observed account of integrative metabolic therapy contributing to disease control when standard options had been exhausted.
Read the full case.
Advanced Lung Cancer with Leptomeningeal Spread
Longer Survival and Better Neurologic Function
This case follows a 49-year-old woman living with advanced non-small-cell lung cancer complicated by leptomeningeal carcinomatosis – a serious and often devastating spread of cancer to the lining of the brain and spinal cord. By the time this diagnosis was made, her health had declined quickly. Neurological symptoms were worsening, her ability to function day to day was limited, and expected survival was measured in weeks to a few months.
She had already been through multiple lines of conventional treatment, including chemotherapy, targeted therapy, and palliative whole-brain radiotherapy. Despite these efforts, the disease continued to progress. Further cancer-directed treatment was not advised, and care conversations had begun to focus on comfort and end-of-life planning. In this setting, Sodium dichloroacetate (DCA) was introduced as an experimental, off-label oral therapy, alongside supportive care.
DCA was started cautiously, with dosing adjusted to reduce the risk any adverse reactions, and was taken in cycles with planned breaks. What followed was unexpected. Within weeks, her family noticed improvements in clarity of thinking, physical strength, and appetite. Over time, her functional status improved, and imaging showed stabilisation along with partial regression of leptomeningeal involvement.
Although the underlying lung cancer continued to evolve, the neurological aspect of her illness remained controlled for an extended period. She lived for approximately 64 weeks after starting DCA, well beyond what is typically seen with leptomeningeal carcinomatosis. During much of this time, she experienced improved comfort and independence.
At follow-up, her course stood out not because the disease was cured, but because time was gained- time marked by clearer thinking, greater ease, and a slower pace of decline. In a condition where options are limited and outcomes are often swift, this case offers a carefully observed account of prolonged survival and neurological stabilisation during treatment with sodium dichloroacetate.
Read the full case.
Metastatic Breast Cancer
Improved Symptoms and Falling Tumor Markers on Dichloroacetate Plus Ivermectin
This case involves a 69-year-old woman living with metastatic breast cancer, with spread to the bones and pleura. By the time this combination approach was considered, she had already undergone several standard treatments, including chemotherapy and hormone-based therapy. These had brought temporary benefit, but the disease continued to progress, and the cumulative side effects of treatment became increasingly difficult to live with. Breathlessness, fatigue, and pain were beginning to shape her daily life.
Against this background, a metabolic combination therapy was introduced. It DCA, ivermectin, and supportive agents such as omeprazole, alongside ongoing tamoxifen. The intention was not to pursue aggressive tumor eradication, but to see whether combining agents with complementary mechanisms could slow disease activity and ease symptoms after conventional options had been exhausted.
What followed was a quiet but noticeable change. The patient reported improvement in breathlessness and pain, making day-to-day activities more manageable. Over the same period, tumor markers showed a downward trend, suggesting a reduction in disease activity. Imaging was consistent with this picture, showing stabilisation rather than continued progression.
The treatment was generally well tolerated, with no major adverse effects reported. Although the response was limited in duration and the disease was not reversed, the period of symptom relief and tumor marker improvement stood out in the context of previously advancing cancer.
This case offers a carefully documented example of short-term disease control and symptom stabilisation in metastatic breast cancer using a dichloroacetate-ivermectin based combination approach.
Read the full case.
Metastatic Osteosarcoma
Quick Improvement in Pain and Breathing After Dichloroacetate Plus Ivermectin
This case describes a patient living with metastatic osteosarcoma, a rare and aggressive bone cancer that can be particularly difficult to control once it spreads. By the time this combination approach was considered, the disease had progressed despite standard treatments, including surgery and chemotherapy. Metastatic involvement had led to significant symptoms, most notably severe pain and increasing shortness of breath, which were beginning to limit daily activity and quality of life.
With conventional options exhausted and the focus shifting toward palliation, a metabolic combination therapy was introduced. This included sodium dichloroacetate (DCA) and ivermectin, alongside supportive medications. The intention was not curative. Rather, it was to explore whether targeting cancer metabolism through complementary mechanisms could ease symptoms and slow disease activity in a setting where few alternatives remained.
What followed was a rapid and noticeable clinical response. Within a short period after starting treatment, the patient reported a marked reduction in pain and an improvement in breathing. These changes were significant enough to reduce reliance on symptom-directed medications and allowed for greater comfort and mobility.
The treatment was generally well tolerated, with no major adverse effects reported during the observation period. While the underlying disease remained advanced, the speed and clarity of symptom improvement stood out against the backdrop of prior decline.
This case offers a carefully observed example of meaningful relief in metastatic osteosarcoma using a dichloroacetate-ivermectin combination.
Read the full case.
Metastatic Lung Cancer
Symptoms Improved After Adjusting Dichloroacetate Plus Ivermectin Treatment
This case involves a patient living with metastatic lung adenocarcinoma, a condition that often brings increasing symptom burden as treatment options become limited. By the time this approach was considered, the disease had progressed despite standard therapies, and symptoms such as breathlessness, fatigue, and declining physical capacity were beginning to shape daily life.
A metabolic combination therapy using Sodium dichloroacetate (DCA) and ivermectin was introduced with the aim of improving symptom control and slowing further decline. Early on, the initial dosing proved difficult to tolerate. Rather than stopping treatment, the regimen was adjusted carefully, with changes to both dose and timing to better suit the patient’s tolerance.
Following these adjustments, the clinical course became more stable. Breathlessness eased, energy levels improved, and everyday activities became easier to manage. Symptom control was noticeably better than in the period before treatment.
The revised regimen was better tolerated, with few side effects reported. Supportive care continued alongside the metabolic approach, with ongoing attention to comfort and quality of life.
This case offers a practical example of how flexible dosing and careful adjustment of a dichloroacetate-ivermectin combination may help stabilise symptoms in advanced lung adenocarcinoma when conventional treatments no longer provide relief.
Read the full case.
Metastatic Angiosarcoma
Tumor Shrinkage and Stable Disease with Dichloroacetate Plus Radiation
This case follows a 43-year-old man living with metastatic angiosarcoma, a rare and aggressive cancer. His medical story was already long and complicated. Years earlier, he had been treated for osteosarcoma with surgery and chemotherapy and had recovered. More than a decade later, a new cancer emerged (angiosarcoma of the right femur) treated again with surgery and chemotherapy, though this time complicated by infection and kidney injury.
Despite these efforts, the disease continued to advance. Over the years that followed, he underwent multiple surgeries to remove lung metastases, radiotherapy to bone lesions, and other local treatments. By late 2011, imaging showed further progression, including spread to the lungs, bones, and pancreas. Conventional options had largely been exhaustedIn that setting, Sodium dichloroacetate (DCA) was introduced as part of an integrative approach. DCA was given alongside supportive metabolic therapies and, for part of the treatment period, targeted radiotherapy to spinal lesions.
Over the months that followed, the picture began to shift. Imaging showed a mixed but meaningful response. Lung metastases remained stable, bone lesions changed little, and a pancreatic metastasis (previously resistant to radiotherapy) decreased in size. No new visceral metastases appeared during this time.
Clinically, the patient remained stable, and the treatment was well tolerated, with no significant treatment-related adverse effects reported.
At follow-up, the case stood out for its partial tumor regression and overall disease stabilisation. While the combined nature of the treatment means the effect cannot be attributed to DCA alone, this case offers a carefully observed example of metabolic therapy contributing to disease control in metastatic angiosarcoma after standard treatments had failed.
Read the full case.
Stomach cancer
Cancer Stabilized Using Sodium Dichloroacetate with Hyperthermia and ALA
This case follows a patient living with scirrhous gastric cancer, an aggressive form of stomach cancer that tends to spread diffusely and respond poorly to standard treatments. By the time this approach was considered, the disease was advanced, and conventional options were limited, with care focused mainly on palliation.
In this context, a combination strategy was introduced that included DCA, regional hyperthermia, and 5-aminolevulinic acid (ALA). Each element served a different purpose. Hyperthermia was used to increase tumor sensitivity, ALA for its role in tumor-selective metabolic and photodynamic processes, and DCA to influence cancer metabolism more broadly.
Over the course of treatment, the situation stabilised. Imaging showed control of tumor growth, with no clear signs of further progression. Symptoms became easier to manage, and the patient’s overall condition remained steady.
The treatment was generally well tolerated. No serious side effects were reported, and supportive care continued alongside therapy.
Read the full case.
Cholangiocarcinoma
CholangiocarcinomaCancer Stabilized Using Sodium Dichloroacetate with Omeprazole and Tamoxifen
This case follows a 51-year-old woman living with cholangiocarcinoma, a cancer of the bile ducts that becomes especially difficult to treat once it advances. By the time this combination approach was considered, she had already been through standard chemotherapy with gemcitabin as well as adoptive immunotherapy using natural killer cells. None had slowed the disease. Progression continued, and treatment options were narrowing.
In that setting, a combination of DCA, omeprazole, and tamoxifen was introduced with the patient’s consent. The choice was guided by laboratory research suggesting that these drugs, when used together, might work more effectively than any one alone. Each medication was already well known in clinical practice, with established safety profiles. The aim was not cure, but to see whether the pace of the disease could be slowed after other options had failed.
What followed was a period of stability. Over the next three months, the patient’s CA19-9 levels (a tumor marker often used to track cholangiocarcinoma) stopped rising. CT scans supported this, showing no clear progression during that time. Clinically, the disease appeared to pause rather than continue its earlier trajectory. The treatment was well tolerated, with no major side effects reported.
Read the full case.
DCA for Endometriosis
Endometriosis can turn life into a monthly negotiation with pain. For many women, it is not just cramps. It can be fatigue, heavy bleeding, bowel or bladder pain, pain with intimacy, and flares that ripple into work, relationships, and mental health.
Most standard approaches aim to suppress hormones or remove lesions surgically. Those options help many people, but not everyone can tolerate them, and not everyone gets lasting relief.
DCA is being explored here for a different reason: endometriosis tissue also shows metabolic features that may be targetable. That is the core idea. Not “magic.” Not “a cure.” A mechanism worth testing.
What makes this feel different is that it represents a genuinely new angle on a disease that has kept too many women stuck in the same loop for years. Instead of only managing symptoms or relying on repeated suppression, the goal is to influence the underlying biology that helps endometriosis persist.
If this approach continues to hold up in larger studies, it could become much more widely used. Progress can be slow, especially when a molecule is not patentable and there is less financial incentive to push it quickly through every stage. Still, the early signals are encouraging, and a growing number of women report meaningful improvements when DCA is used thoughtfully and consistently.
What shows up most often in DCA endometriosis stories is a simple pattern: pain scores drop, daily function improves, and periods become more manageable. In a smaller number of documented reports, imaging has shown cysts shrinking over time.
We hope these stories and summaries help you make an informed decision about whether this is something worth exploring for your own situation.
If you want the stories and the research path in one place, start here:
Story-Style Diary (Week-by-Week Experience):
• Testing DCA for Endometriosis: A Young Woman’s Five Week Diary
Evidence and Media Coverage:
DCA for Endometriosis – Experiences:
• My Personal DCA Trial for Endometriosis | What It Is, Side Effects, and My Supplement Routine
• Endometriosis: How new treatment ‘changed my life’
A Practical Way to Use This Page
If you are new to DCA, do not try to absorb everything at once.
Pick your track: cancer or endometriosis. Then read the deeper page slowly. Look for what is measurable. Look for timelines. Look for what was tried before DCA and what changed after.
Then start with dosing, because details matter.
Use the dosage calculator to match your plan to your body weight and your goal. Download the personalized PDF protocol it generates, so you have a clear schedule you can follow and review. Then take a few minutes to read the section on the key supplements commonly used with DCA, especially the ones people use to reduce side effects and make the experience smoother.
Start with dosing and a printable plan:
• DCA Dosage Calculator (based on weight and goal)
Learn the support pieces that matter most:
• Key Supplements With DCA
• Side effects and how people reduce them (practical notes)
After that, come back to the case reports and timelines with a sharper eye. It becomes much easier to judge whether DCA could realistically fit your own situation when you understand the dose, the schedule, and the support pieces that usually go with it.
We hope this helps you weigh your options and choose what feels most reasonable for you.
